BiotechTube
Beactica Therapeutics

Beactica Therapeutics

Uppsala, Sweden· Est.
beactica.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $22M

Overview

Beactica Therapeutics is an emerging, private biotech transitioning from a service-oriented fragment-based lead generation (FBLG) company to a therapeutics developer with a proprietary pipeline. Its core asset is the Eclipsor™ platform, which integrates allosteric modulation and targeted protein degradation to create novel therapeutics. The company has a validated track record through prior partnerships, has received FDA Orphan Drug Designation for its lead asset BEA-17 in glioblastoma, and is positioned as a 'TPD Company to Watch' with ambitions to become a clinical-stage precision oncology company.

Oncology

Technology Platform

Eclipsor™ platform integrating allosteric modulation and targeted protein degradation (TPD/PROTACs) to drug 'undruggable' targets, built on a foundation of fragment-based lead generation (FBLG) using SPR biosensor technology.

Funding History

4
Total raised:$22M
Series A$8M
Series A$8.5M
Seed$2.5M
Seed$3M

Opportunities

The large and growing precision oncology market, combined with the ability to address the vast 'undruggable' proteome via Targeted Protein Degradation, presents a major opportunity.
Orphan Drug Designation for glioblastoma offers a faster regulatory pathway and market exclusivity.
The company's validated platform and strong partnership history position it well for future strategic deals.

Risk Factors

High scientific risk associated with preclinical drug development and the novel TPD modality.
Significant funding risk as a private, pre-revenue company needing capital to reach clinical trials.
Intense competition in the TPD and oncology spaces from larger, well-funded entities.

Competitive Landscape

Beactica competes in the rapidly evolving Targeted Protein Degradation field against dedicated public TPD companies (e.g., Arvinas, Kymera, Nurix) and large pharmaceutical firms with internal programs. Its differentiation lies in the integration of allosteric modulation with TPD via its Eclipsor™ platform and its focused pipeline in genetically defined cancers.

More companies in Small Molecule Drugs →More companies in Sweden →